Karyopharm Therapeutics Inc. (KPTI) Stock Price & Analysis
Karyopharm Therapeutics Inc. (KPTI) rose 2.24% to USD 8.69 as of June 10, 2026 at 02:14 UTC, according to Nexqual real-time market data.
KPTI last closed at USD 8.5; the session ranged USD 8.44–9 on volume of 323,609 shares. Market capitalization is $196.94M, with a 52-week range of USD 3.65–10.99 (NMS). Source: Nexqual, June 10, 2026 at 02:14 UTC.
Key Statistics (as of June 10, 2026 at 02:14 UTC)
| Price | USD 8.69 |
|---|---|
| Change | ▲ 2.24% (up) |
| Previous Close | USD 8.5 |
| Open | USD 8.68 |
| Day Range | USD 8.44 – 9 |
| 52-Week Range | USD 3.65 – 10.99 |
| Volume | 323,609 shares |
| Market Cap | $196.94M |
| Exchange | NMS |
Technical Analysis (KPTI)
Nexqual's technical model rates KPTI "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:14 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 46.79 (neutral) |
| vs SMA50 | Above (USD 8.33) |
| MACD | 0.14 (positive) |
Analyst Ratings (KPTI)
Wall Street analysts rate KPTI "Buy" based on 6 analysts, with a mean price target of USD 13.5 (range USD 7–16), per Nexqual as of June 10, 2026 at 02:14 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 13.5 |
| High Target | USD 16 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (KPTI)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -1.39 |
| Revenue Estimate | $33.12M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.24 vs est -1.44 ▲ beat |
| 2025-12-31 | USD -2.23 vs est -2 ▼ miss |
| 2025-09-30 | USD -3.82 vs est -3.25 ▼ miss |
| 2025-06-30 | USD -4.07 vs est -3.91 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financials & Fundamentals (KPTI)
| Total Revenue | $151.12M |
|---|---|
| Revenue Growth (YoY) | +16.80% |
| Gross Margin | +13.45% |
| Operating Margin | -76.31% |
| Profit Margin | -129.02% |
| Total Cash | $90.85M |
| Total Debt | $296.73M |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financial Health Score (KPTI)
Nexqual rates Karyopharm Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:14 UTC.
| Growth | Mixed — Revenue +0.6% YoY (annual), slow |
|---|---|
| Profitability | Critical — Gross margin 13%, operating -76% |
| Balance Sheet | Mixed — $91M cash vs $297M debt |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (KPTI)
| Insider Ownership | +4.68% |
|---|---|
| Institutional Ownership | +83.69% |
| Shares Outstanding | 22.66M |
| Float | 14.70M |
| Short % of Float | +23.72% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Leadership (KPTI)
Karyopharm Therapeutics Inc. is led by Richard A. Paulson (age 58), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:14 UTC.
| President, CEO & Director | Richard A. Paulson (age 58) |
|---|---|
| Co-Founder & Chairman of Scientific Advisory Board | Sharon Shacham (age 55) |
| EVP, CFO & Treasurer | Lori A. Macomber (age 54) |
| Senior Vice President of Investor Relations | Brendan Twohig Strong |
Major Backers & Investors (KPTI)
Notable institutional backers of Karyopharm Therapeutics Inc. include T. Rowe Price, Commodore Capital Lp, RA Capital Management, L.P., according to Nexqual as of June 10, 2026 at 02:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 10.67% |
| Commodore Capital Lp | 8.6% |
| RA Capital Management, L.P. | 8.46% |
| Adage Capital Partners GP L.L.C. | 7.97% |
| Goldman Sachs | 4.18% |
| Catalio Capital Management, LP | 3.96% |
| Ikarian Capital, LLC | 3.24% |
| -Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 2.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.46% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
From Karyopharm Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
- The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
- Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| HRTX | Heron Therapeutics, Inc. | USD 0.4 | ▼ 5.84% |
| KYNB | Kyntra Bio, Inc. | USD 6.69 | ▼ 0.3% |
| ATRA | Atara Biotherapeutics, Inc. | USD 9.77 | ▼ 1.51% |
| TGTX | TG Therapeutics, Inc. | USD 43.37 | ▲ 7.99% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:14 UTC. This page is informational and not investment advice.